Phio Pharmaceuticals Corp. (PHIO) AI Stock Analysis

Phio Pharmaceuticals Corp., headquartered in Marlborough, Massachusetts, develops immuno-oncology therapeutics using its INTASYL platform, which targets tumor and immune cells by modulating genes. Its pipeline includes PH-762 to reduce PD-1 expression and enhance adoptive cell transfer (ACT) immunotherapy, PH-894 to target the epigenetic protein BRD4, and PH-804 to target the suppressive immune receptor TIGIT on T cells and natural killer cells. In collaboration with AgonOx Inc., the company is advancing the clinical development of novel T cell-based cancer immunotherapies.

Phio Pharmaceuticals has generated minimal commercial revenues while funding drug development. Annual revenue moved from $19,000 in FY2016 to $15,000 in FY2017, $138,000 in FY2018, $21,000 in FY2019, and $4,362 in FY2020, representing a 5-year revenue CAGR of -33.7% from FY2015 to FY2020. Annual net losses were -$9.0M in FY2016, -$12.5M in FY2017, -$7.4M in FY2018, -$8.8M in FY2019, and -$8.8M in FY2020, when operating margin was -201581.8%. For the trailing twelve months ended June 30, 2026, revenue stood at $0, operating margin was 0.0%, and EPS was -$1.29.

As of June 30, 2026, Phio Pharmaceuticals held $13.0M in cash and short-term investments, total assets of $14.3M, and shareholders' equity of $12.6M. The company reported a current ratio of 15.87. In FY2020, operating cash flow was -$8.8M and free cash flow was -$8.8M. For FY2025, capital expenditures were $12,000. Over a 5-year period, the company's share count increased by 9179.0%.

At a last close of $0.87 on October 16, 2026, Phio Pharmaceuticals has a market capitalization of $10.1M and an enterprise value of -$1.1M. The stock trades at a price-to-book ratio of 0.9x and a forward P/E of 0.3x, compared to a forward P/E of 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales multiple is 48.0x versus the peer median of 4.1x. Over the trailing year, PHIO returned -58.9% compared to 16.8% for the S&P 500 (SPY), while its 5-year return is -99.5% versus 83.0% for the index.

Wall Street analyst coverage consists of 1 Strong Buy rating, 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $14.00, representing a 1507.3% premium over the last close of $0.87. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and EPS of -$1.45. For the following fiscal year, 2 analysts project $0 in revenue and an EPS of -$0.61. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Phio Pharmaceuticals Corp. (PHIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PHIO income statement, PHIO balance sheet, PHIO key metrics, PHIO analyst forecast, PHIO chart. See the PHIO stock overview for the latest quote and news.